147 related articles for article (PubMed ID: 28026820)
1. Mechanisms of angiogenesis in neoplasia.
Sobocińska AA; Czarnecka AM; Szczylik C
Postepy Hig Med Dosw (Online); 2016 Dec; 70(0):1166-1181. PubMed ID: 28026820
[TBL] [Abstract][Full Text] [Related]
2. [Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology].
Mross K
Pharm Unserer Zeit; 2008; 37(5):404-15. PubMed ID: 18729270
[No Abstract] [Full Text] [Related]
3. Inappropriate dose of multitargeted tyrosine kinase inhibitors: the original sin.
Kotecki N; Penel N
Curr Opin Oncol; 2016 Sep; 28(5):437-40. PubMed ID: 27428364
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic drugs and tyrosine kinases.
Tímár J; Döme B
Anticancer Agents Med Chem; 2008 Jun; 8(5):462-9. PubMed ID: 18537529
[TBL] [Abstract][Full Text] [Related]
5. [Tumor angiogenesis: new approaches to cancer therapy].
Marmé D
Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
[TBL] [Abstract][Full Text] [Related]
6. Current overview of angiogenesis inhibitors.
Ellis LM
Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
[No Abstract] [Full Text] [Related]
7. Is VEGF a predictive biomarker to anti-angiogenic therapy?
Otrock ZK; Hatoum HA; Musallam KM; Awada AH; Shamseddine AI
Crit Rev Oncol Hematol; 2011 Aug; 79(2):103-11. PubMed ID: 20724177
[TBL] [Abstract][Full Text] [Related]
8. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink KJ; Verheul HM
Angiogenesis; 2010 Mar; 13(1):1-14. PubMed ID: 20012482
[TBL] [Abstract][Full Text] [Related]
9. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
10. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.
Mena AC; Pulido EG; Guillén-Ponce C
Anticancer Drugs; 2010 Jan; 21 Suppl 1():S3-11. PubMed ID: 20110785
[TBL] [Abstract][Full Text] [Related]
11. Synopsis of angiogenesis inhibitors in oncology.
Ellis LM; Liu W; Fan F; Jung YD; Reinmuth N; Stoeltzing O; Takeda A; Akagi M; Parikh AA; Ahmad S
Oncology (Williston Park); 2002 May; 16(5 Suppl 4):14-22. PubMed ID: 12102576
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis inhibitors in cancer therapy.
Dredge K; Dalgleish AG; Marriott JB
Curr Opin Investig Drugs; 2003 Jun; 4(6):667-74. PubMed ID: 12901224
[TBL] [Abstract][Full Text] [Related]
13. New advances in the research of clinical treatment and novel anticancer agents in tumor angiogenesis.
Li X; Zhou J; Wang X; Li C; Ma Z; Wan Q; Peng F
Biomed Pharmacother; 2023 Jul; 163():114806. PubMed ID: 37163782
[TBL] [Abstract][Full Text] [Related]
14. Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy.
Bronte G; Bronte E; Novo G; Pernice G; Lo Vullo F; Musso E; Bronte F; Gulotta E; Rizzo S; Rolfo C; Silvestris N; Bazan V; Novo S; Russo A
Expert Opin Drug Saf; 2015 Feb; 14(2):253-67. PubMed ID: 25494575
[TBL] [Abstract][Full Text] [Related]
15. [Angiogenesis and antiangiogenic cancer therapy].
Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic cancer therapy.
Cao Y
Semin Cancer Biol; 2004 Apr; 14(2):139-45. PubMed ID: 15018898
[TBL] [Abstract][Full Text] [Related]
17. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic inhibition of angiogenesis.
Zhang HT; Bicknell R
Mol Biotechnol; 2003 Oct; 25(2):185-200. PubMed ID: 14526126
[TBL] [Abstract][Full Text] [Related]
19. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors.
Scott AJ; Messersmith WA; Jimeno A
Drugs Today (Barc); 2015 Apr; 51(4):223-9. PubMed ID: 26020064
[TBL] [Abstract][Full Text] [Related]
20. Current strategies and future directions of antiangiogenic tumor therapy.
Zhang ZL; Wang JH; Liu XY
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Oct; 35(10):873-80. PubMed ID: 14515202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]